Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis

S. Vegter, K. Tolley, M.S. Keith, M.J. Postma

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)
305 Downloads (Pure)

Abstract

Objectives: Hyperphosphatemia is a common and harmful condition in patients with chronic kidney disease (CKD). We determined the cost-effectiveness of the noncalcium-based phosphate binder lanthanum carbonate (LC) as second-line treatment of hyperphosphatemia after therapy failure with calcium-based binders (CB). Methods: Two CKD populations were modeled: 1) predialysis CKD patients and 2) incident dialysis patients. Patients not responding to CB with a serum phosphate (SP) level >5.5 mg/dl received a trial with LC. Patients not responding to LC (SP >4.6 mg/dl) returned to CB treatment. Patient-level data were obtained from clinical trials in predialysis and dialysis. Time-dependent, life-long Markov models (discounting at 3.5% annually) were developed, using a UK National Health Service perspective. Results: The health gains with second-line LC treatment compared to CB treatment were 44 and 56 quality-adjusted life-years (QALYs) for the predialysis and incident dialysis populations, respectively. Second-line LC was a cost-saving strategy in the predialysis population because of the cost-savings of delayed CKD progression. Second-line LC was cost-effective at 6900 pound (90% probability interval: 5800- pound 8300) pound per QALY gained in the dialysis population. Results were robust to plausible variations in other model parameters; inclusion of future unrelated dialysis costs had a large influence on cost-effectiveness estimates. Conclusions: Second-line treatment with LC is associated with considerable clinical benefits and good value for money in CKD, irrespective of dialysis status. These results support Kidney Disease Outcomes Quality Initiative guidelines to treat CKD patients with hyperphosphatemia irrespective of dialysis status.

Original languageEnglish
Pages (from-to)852-858
Number of pages7
JournalValue in Health
Volume14
Issue number6
DOIs
Publication statusPublished - 2011

Keywords

  • chronic kidney disease
  • cost-effectiveness
  • end-stage renal disease
  • hyperphosphatemia
  • lanthanum carbonate
  • phosphate binders
  • STAGE RENAL-DISEASE
  • QUALITY-OF-LIFE
  • MAINTENANCE HEMODIALYSIS-PATIENTS
  • MINERAL METABOLISM
  • ECONOMIC EVALUATIONS
  • PHOSPHATE BINDERS
  • SERUM PHOSPHATE
  • PREDIALYSIS PATIENTS
  • CALCIUM-CARBONATE
  • MORTALITY RISK

Cite this